JPRN-UMIN000000462已完成3 期
Validation study VI of febrile neutropenia guideline 2004 - Treatment for FN in high-risk patients
Japan Febrile Neutropenia Study Group0 个研究点目标入组 400 人开始时间: 2006年8月4日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 16years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Isolation of microorgaism resistant to the study drug 2.Serious cardiac, liver or renal dysfunction 3.Past history of allergy to beta-lactum 4.Allergic diathesis 5.Positive skin reaction to study drug if it has to be done by each institution's regulation 6.Elderly patients who can not be evaluated for efficacy 7.Pregnant or lactating woman 8.Age of 15 years or younger 9.Antimicrobial treatment within 3 months prior to the study entry 10.Allogenic hematopoietic stem cell transplantation and older person 11.Patients to exclude from the study by primary physician's decision
研究者
相似试验
已完成
3 期
Validation study of new febrile neutropenia guideline-Comparative study between oral levofloxacin and parenteral cefepime in low-risk patients with febrile neutropeniaFebrile neutropeniaJPRN-C000000396Japan Febrile Neutropenia Study Group200
已完成
不适用
A Study of Neutropenia and Anemia Management in Patients With Solid Tumors Receiving Myelotoxic ChemotherapyBreast CancerOvarian CancerNon-Small Cell Lung CancerSmall Cell Lung CancerNCT00883181Amgen1,370
已完成
不适用
Study of patient risk factors for febrile neutropenia in NHL receiving (R)CHOP regimen 2on Hodgkin's LymphomaJPRN-UMIN000029534The Cancer Institute Hospital Of JFCR239
进行中（未招募）
不适用
Phase IV study to investigate neutrophil downregulation of Thy-1 by Raptiva® (Efalizumab) as a potential responder predictor in patients with moderate to severe plaque psoriasis - Responder Prediction StudyModerate to severe chronic plaque psoriasis (PASI = 12) failing to respond to, or with a contraindication to, or intolerant to other systemic therapies including cyclosporine, methotrexate and Psoralen ultraviolet light A (PUVA)MedDRA version: 8.1Level: LLTClassification code 10050576Term: Psoriasis vulgarisEUCTR2006-004547-35-DESerono GmbH
尚未招募
1 期
Functional evaluation of neutrophil of patients at high risk for infection treated with monocyte/ neutrophil apheresisJPRN-UMIN000012245Mie University Hospital40